Average Insider

Where insiders trade, we follow

$IMA
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Mark Manfredi
CEO
10
Employees
$5.76
Current Price
$718.82M
Market Cap
52W Low$3.94
Current$5.7613.0% above low, 87.0% below high
52W High$17.96

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells12$17,334.003,196
2 monthsBuys00--All Sells
Sells12$17,334.003,196
3 monthsBuys00--All Sells
Sells12$17,334.003,196
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 17, 2026
Lally Robert B
Principal Accounting Officer
Sale1,525$5.34$8,143.50View Details
Jul 16, 2026
Lally Robert B
Principal Accounting Officer
Sale1,671$5.50$9,190.50View Details
1 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.7.3